NASDAQ: SYNHSyneos Health Inc Stock
$42.74-0.03 (-0.07%)
Updated Sep 22, 2023
SYNH Price
$42.74
Fair Value Price
N/A
Market Cap
$4.43B
52 Week Low
$22.89
52 Week High
$52.23
P/E
61.06x
P/B
1.27x
P/S
0.81x
PEG
0.37x
Dividend Yield
N/A
Revenue
$5.42B
Earnings
$71.22M
Gross Margin
22.1%
Operating Margin
3.62%
Profit Margin
1.3%
Debt to Equity
1.31
Operating Cash Flow
$253M
Beta
1.25
Next Earnings
Nov 2, 2023
Ex-Dividend
N/A
Next Dividend
N/A
SYNH Overview
Syneos Health, Inc. provides biopharmaceutical outsourcing solutions company in North America, Europe, the Middle East, Africa, the Asia-Pacific, and Latin America. It operates through two segments, Clinical Solutions and Commercial Solutions. The Clinical Solutions segment offers services for the development of diagnostics, drugs, biologics, devices, and digital therapeutics in the Phase I to IV of clinical development. This segment also provides individual services, including product development and regulatory consulting, project management, protocol development, investigational site recruitment, clinical monitoring, technology-enabled patient recruitment and engagement, clinical home health, clinical trial diversity, biometric, and regulatory affair services. The Commercial Solutions segment provides commercialization services, including deployment solutions, communications solutions, such as public relations, advertising, and medical communication services; and consulting services to the pharmaceutical, biotechnology, and healthcare industries. The company was formerly known as INC Research Holdings, Inc. and changed its name to Syneos Health, Inc. in January 2018. Syneos Health, Inc. was incorporated in 2010 and is headquartered in Morrisville, North Carolina.
Zen Score
–
Industry Average (27)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how SYNH scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
SYNH ($42.74) is trading above its intrinsic value of $38.98, according to an updated version of Benjamin Graham's Formula from Chapter 11 of "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
SYNH is poor value based on its earnings relative to its share price (61.06x), compared to the US market average (14.52x)
P/E vs Market Valuation
SYNH is poor value based... subscribe to Premium to read more.
P/E vs Industry Valuation
There are 30 more SYNH due diligence checks available for Premium users.
Be the first to know about important SYNH news, forecast changes, insider trades & much more!
SYNH News
Valuation
SYNH fair value
Fair Value of SYNH stock based on Discounted Cash Flow (DCF)
Price
$42.74
Fair Value
$43.85
Undervalued by
2.54%
SYNH ($42.74) is trading above... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
SYNH price to earnings (PE)
For valuing profitable companies with steady earnings
Company
61.06x
Industry
25.9x
Market
14.52x
SYNH is poor value based... subscribe to Premium to read more.
P/E vs Industry Valuation
SYNH is poor value based... subscribe to Premium to read more.
P/E vs Market Valuation
SYNH price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
1.27x
Industry
3.92x
SYNH is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
SYNH price to earnings growth (PEG)
For valuing profitable companies with growth potential
SYNH is good value based... subscribe to Premium to read more.
PEG Value Valuation
SYNH's financial health
Profit margin
Revenue
$1.4B
Net Income
$793.0k
Profit Margin
0.1%
SYNH's Earnings (EBIT) of $196.08M... subscribe to Premium to read more.
Interest Coverage Financials
SYNH's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$8.1B
Liabilities
$4.6B
Debt to equity
1.31
SYNH's short-term assets ($1.95B) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
SYNH's long-term liabilities ($2.95B) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
SYNH's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
SYNH's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$33.7M
Investing
-$18.9M
Financing
$25.9M
SYNH's operating cash flow ($252.93M)... subscribe to Premium to read more.
Debt Coverage Financials
SYNH vs Diagnostic & Research Stocks
Syneos Health Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.